i believe an FDA phase IV clinical is required to prove the vaccine is effective after the drug is on the market.
bill, you are right on the publication aspect and if the results compare favorably to other Q flu vaccines we have a superior vaccine by virtue of the neuraminidase inhibitor
I do not know whether or not you saw the release by the Univ of Penn on the immune system responding to a parasite,but this development could lead to a new avenue for the vlp tech or possibly the use of miscelles.
I also note that the possible development of a universal vaccine is based on vlp or micelles binding to conserved part of the influenza virus, the stalk.
We are in the right place,at the right time,and in the right field..
Your right about resident immune cells residing in tissues that respond to viruses and other pathogens. Your also right I should have been more specific. The new finding is that memory T-cells respond to a parasite infection and it could lead to effective vaccines against parasitic diseases.It's the first time researchers have discovered an immune response against a parasite. It's an important finding.
A new finding shows that certain immune cells reside in tissues and that when a pathogen is encountered they invoke an immune response. This is the first time immune cells were found to reside in tissues and cause genes involved in an immune response. to increase in production.
The finding could lead to the design of vaccines responsible for diseases that infect different tissues. It's another avenue for researchers at Novavax to explore.
We are in the right place,at the right time,and in the right field.
If there is a suitor, I like Pfizer. Their latest earnings report featured their vaccine division contributing to their higher earnings.
Also, today's trading is showing that there's a seller.
sno, you're interpreting the statement in the wrong way. The authors are saying that before the the research was done the mechanism of action of TB4 was unknown, but now it is. The entire abstract explains what takes place to regrow hair in mice. IT IS THE MECHANISM OF ACTION!
Let's see how the research progresses before making any judgements as to the market value. If there's a way to grow hair such that it's thick and completely covers then a premium can be charged for the product. Now that the mechanism of action is known the call for improvements by major players is possible.
Researchers have discovered the mechanism of how TB4 regrows hair. With this discovery it should be easier to improve on the regrowth of regrowth.
PLoS One. 2015 Jun 17;10(6):e0130040. doi: 10.1371/journal.pone.0130040. eCollection 2015.
Thymosin Beta-4 Induces Mouse Hair Growth.
Gao X1, Liang H1, Hou F1, Zhang Z1, Nuo M1, Guo X1, Liu D1.
Thymosin beta-4 (Tβ4) is known to induce hair growth and hair follicle (HF) development; however, its mechanism of action is unknown. We generated mice that overexpressed Tβ4 in the epidermis, as well as Tβ4 global knockout mice, to study the role of Tβ4 in HF development and explore the mechanism of Tβ4 on hair growth. To study Tβ4 function, we depilated control and experimental mice and made tissue sections stained with hematoxylin and eosin (H&E). To explore the effect of Tβ4 on hair growth and HF development, the mRNA and protein levels of Tβ4 and VEGF were detected by real-time PCR and western blotting in control and experimental mice. Protein expression levels and the phosphorylation of P38, ERK and AKT were also examined by western blotting. The results of depilation indicated that hair re-growth was faster in Tβ4-overexpressing mice, but slower in knockout mice. Histological examination revealed that Tβ4-overexpressing mice had a higher number of hair shafts and HFs clustered together to form groups, while the HFs of control mice and knockout mice were separate. Hair shafts in knockout mice were significantly reduced in number compared with control mice. Increased Tβ4 expression at the mRNA and protein levels was confirmed in Tβ4-overexpressing mice, which also had increased VEGF expression. On the other hand, knockout mice had reduced levels of VEGF expression. Mechanistically, Tβ4-overexpressing mice showed increased protein expression levels and phosphorylation of P38, ERK and AKT, whereas knockout mice had decreased levels of both expression and phosphorylation of these proteins.see pub med.
The recent CIDRAP article shows the direction new flu vaccines will take. The information will serve as a template to Novavax and investors alike. It's a must read.
The patent appears secondary to two US patents recently approved by the USPTO that are the primary focus of RGRX's technology and the patent allowance maybe useful for a future development.
wily, the platform is "OURS" and NVAX is the key to producing the next generation VLP vaccines. It can't get much better than this.
but it is, just ask the researchers at Novavax. And today's price rise is somewhat based upon the NIAID article.
The news should give us a good indication of what to expect when the quadrivalent seasonal influenza results are announced.
We are in the right place at the right time and in the right field.
Virus-like particle vaccine protects mice from many flu strains
NIAID research could aid development of universal flu vaccine
NIH/National Institute of Allergy and Infectious Diseases
A vaccine that protects against a wide variety of influenza viruses (a so-called universal flu vaccine) is a critical public health goal given the significant rates of illness and death caused by seasonal influenza and the potentially devastating effects of a pandemic influenza strain. Now, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have devised a way to induce protective immunity in mice against a wide array of influenza viruses.
Instead of trying to predict which influenza virus strains are likely to cause human disease and then make a vaccine to match those specific strains, Jeffery Taubenberger, M.D., Ph.D., and his colleagues created a vaccine cocktail incorporating four of the 16 different subtypes of an influenza virus protein called hemagglutinin (H). Two, H1 and H3, are typically found in human seasonal influenza viruses, and two, H5 and H7, are from avian influenza viruses that can also infect people. The experimental vaccine is made from non-infectious virus-like particles (VLPs) that stimulate an immune response, but that cannot replicate or cause disease. VLP vaccines already approved for use in people include those to protect against hepatitis B and human papillomavirus.
In the new study, the NIAID scientists vaccinated mice with the VLP cocktail, then exposed them to lethal doses of several different influenza viruses. Importantly, in some of the experiments, mice were exposed to viruses from H subtypes not included in the cocktail vaccine. Vaccinated mice showed significant protection following challenge with influenza viruses expressing 1918 H1, 1957 H2, and avian H5, H6, H7, H10, and H11 H subtypes. There's more: see mBio
It would appear you're right. There's a potential problem with what the MM is doing, shorting or naked shorting and that's he keeps accumulating shares. A major announcement accompanied by huge volume for a protracted time will cause trouble.
agreed, A while ago I bid at .13 with Ameritrade and the crossed it at .14. I called to complain and the MM reversed the trade. Games are being played at our expense. We need to leave this exchange asap.
Your statement is logical it would appear that the SEC is allowing "ordinary course of business trades" and POSITION trades to be considered the same, regardless of what the regulation states. In practice both are one and the same. FINRA figures are significant and should RGRX technology prove successful NITE and other MM's may cover. It most likely take more than one successful clinical for the MM's to consider covering.
Additionally, the MM's will cover sooner if and when RGRX finds a large pharma company to partner with in neuro or heart.